Moderna Inc (MIL:1MRNA)
€ 38.165 -0.445 (-1.15%) Market Cap: 14.61 Bil Enterprise Value: 9.32 Bil PE Ratio: 0 PB Ratio: 1.30 GF Score: 44/100

Moderna Inc at BMO Capital Markets Prescription for Success Healthcare Conference Transcript

Jun 25, 2019 / 07:20PM GMT
George Farmer
BMO Capital Markets Equity Research - Analyst

Good afternoon, everyone. My name is George Farmer. I'm a biotechnology analyst here at BMO. It's my pleasure to have Pam Cohen here with us here from Moderna. She's the head of Oncology Clinical Development at the company. And she's going to talk to us about Moderna's platform and its application in oncology indication specifically, and how Moderna is using messenger RNA-based vaccines for treating cancer.

Questions & Answers

George Farmer
BMO Capital Markets Equity Research - Analyst

So Pam, why don't we start off, perhaps you could just walk us through the approach that Moderna is using involving messenger RNA-based vaccine?

Pamela S. Cohen
Moderna, Inc. - Head of Clinical Oncology Development

Sure. And thank you for having me, George. So we know that mutation-derived epitopes are important to activate T cells in patients with cancer and they drive, to some extent, the antitumor response that is seen with checkpoint inhibitors, and that's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot